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Abstract 
Purpose: Large-panel genomic tumor testing (GTT) is an emerging technology with great promise but uncertain 
clinical value. Previous research has documented variability in academic oncologists’ perceptions and use of GTT, but 
little is known about community oncologists’ perceptions of GTT and how perceptions relate to clinicians’ intentions 
to use GTT.
Methods: Community oncology physicians (N = 58) participating in a statewide initiative aimed at improving 
access to large-panel GTT completed surveys assessing their confidence in using GTT, attitudes regarding the value 
of GTT, perceptions of barriers to GTT implementation, and future intentions to use GTTs. Descriptive and multivari-
able regression analyses were conducted to characterize these perceptions and to explore the relationships between 
them.
Results: There was substantial variability in clinicians’ perceptions of GTT. Clinicians generally had moderate confi-
dence in their ability to use GTT, but lower confidence in patients’ ability to understand test results and access tar-
geted treatment. Clinicians had positive attitudes regarding the value of GTT. Clinicians’ future intentions to use GTT 
were associated with greater confidence in using GTT and greater perceived barriers to implementing GTT, but not 
with attitudes about the value of GTT.
Conclusions: Community oncologists’ perceptions of large-panel genomic tumor testing are variable, and their 
future intentions to use GTT are associated with both their confidence in and perceived barriers to its use, but not 
with their attitudes towards GTT. More research is needed to understand other factors that determine how oncolo-
gists perceive and use GTT in clinical practice.
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Introduction
Genomic tumor testing is an emerging technology that 
promises to improve cancer treatment outcomes and has 
already enabled successful targeted, “precision” treat-
ments for common and difficult to treat cancers. Promi-
nent examples include erlotinib for EGFR-mutant lung 
cancer [1] and vemurafenib for BRAF V600E–mutant 
melanoma [2]. Tumor tests for mutations with known 
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FDA-approved treatments have quickly become the 
standard of care. In recent years, next-generation genome 
sequencing technology has enabled the development of 
large-panel genomic tumor tests (GTT) that can test and 
identify variants in hundreds of genes simultaneously. 
However, for many variants identified by large-panel 
GTT no current FDA-approved treatments exist, and 
the clinical utility of these extended, large-panel testing 
is debatable. Nevertheless, GTT is increasingly utilized 
in clinical practice. In a 2017 study, 75.6% of oncologists 
reported currently using multi-gene GTT to guide treat-
ment decisions [3]. Moreover, as genomic technologies 
become less expensive and more accurate [4], utilization 
of GTT will likely increase and continue to identify more 
genomic variants with uncertain clinical utility [5–7].
These associated uncertainties, along with the increas-
ing dissemination and implementation of GTT in clinical 
practice, make it important to understand how oncolo-
gists perceive, understand, and actually use this tech-
nology. Past research on this topic, however, has been 
limited and focused primarily on academic oncologists’ 
confidence in using GTT. Gray et al. conducted a single-
institution study of academic medical oncologists, and 
found variability in clinicians’ confidence in their knowl-
edge of GTT and their ability to both explain GTT to 
patients and to make treatment recommendations based 
on genomic information [8]. More recent studies have 
yielded mixed findings regarding physicians’ understand-
ing and confidence in their ability to interpret, use, and 
discuss the results of GTT with patients [9, 10]. These 
mixed findings may reflect differences in the clinical 
settings, disease types, and sample populations of these 
studies, and raise the need for further research.
More research is also needed to investigate how clini-
cians’ perceptions of GTT influence their utilization of 
these tests. Gray et  al. demonstrated that greater confi-
dence in the use of GTT among oncologists was associ-
ated with greater anticipated future use of GTT [8]. This 
finding is consistent with theories of health behavior, 
which theorize that confidence—also referred to as self-
efficacy [11]—is a critical determinant of health behav-
ior. However, past studies of GTT have not investigated 
the potential influence of other factors thought to be 
equally critical, including attitudes regarding the value 
of GTT and perceptions of barriers to GTT utilization. 
Most research on clinicians’ perceptions of GTT has also 
been limited to oncologists practicing at large academic 
medical centers (e.g. [8, 9, 12],); clinicians practicing in 
community-based settings and rural areas have received 
less attention. Emerging evidence suggests, however, that 
community oncologists may use GTT less frequently 
[13] and that oncologists in rural areas might have more 
limited genomic knowledge [14]. More research is thus 
needed to characterize the knowledge, attitudes, and 
practices of community oncologists in more rural set-
tings, given that most cancer care in the US is provided in 
such settings, and many rural communities have dispro-
portionately high cancer incidence and mortality rates 
[15].
The objective of this study was to understand com-
munity oncology clinicians’ perceptions of GTT and 
how they relate to clinicians’ intentions to use GTT. 
We focused on three types of perceptions theoretically 
related to GTT use: confidence (self-efficacy) regarding 
the use of GTT; attitudes regarding the value of GTT; 
and perceived barriers to implementing GTT (e.g. cost, 
incidental germline findings). Major health behavior the-
ories hold that behavioral intentions are key precursors 
of actual health behaviors [16, 17]. We therefore treated 
future intentions to use GTT as a proxy for actual test-
ordering behavior, in order to explore how clinicians’ 
various perceptions of GTT might be related to their use 
of the test.
This study leveraged a unique program, the Maine 
Cancer Genomics Initiative (MCGI), designed to over-
come the implementation hurdles for large-panel GTT 
and precision oncology in rural community settings. The 
MCGI is a ten-year (2016–2026), longitudinal, state-
wide, multi-site initiative aimed at disseminating GTT in 
community oncology practices throughout the State of 
Maine. The MCGI provides clinicians and their patients 
with access to free large-panel GTT as well as clini-
cian education and decision support services, including 
genomic tumor boards conducted at multiple practice 
sites throughout the state. The MCGI thus provided a 
unique opportunity to assess how community-based 
oncologists in a predominantly rural state perceive and 
use GTT in their practices.
Methods
Study population and design
The study population consisted of actively practicing 
oncology physicians in Maine, including hematologists/
oncologists, gynecologic oncologists, and surgical oncol-
ogists. Physicians were recruited by the MCGI research 
team via in-person site visits, email, and telephone. 
Informed consent was obtained from all participants. 
Upon joining the MCGI, participating clinicians com-
pleted a 30-min baseline survey containing a variety of 
measures, including sociodemographic and practice 
information, as well as clinicians’ perceptions and future 
intentions to use GTT. The survey was self-adminis-
tered using the online survey platform RedCap Cloud™ 
between June 2017 and October 2018. The MCGI study 
protocol was reviewed and approved by the Western 
Institutional Review Board. This study was performed in 
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accordance with the ethical standards of the Declaration 
of Helsinki or comparable ethical standards.
Measures
The survey questionnaires contained items measuring 
the following constructs (see supplemental online Table 1 
for exact wording and response options for each survey 
question). Questionnaire items were developed by adopt-
ing or adapting existing measures in the literature, as 
noted below, or developing new items which were piloted 
among 3 practicing medical oncologists and further 
refined by our team.
Future intentions to use GTT 
Clinicians’ intentions to use GTT in the future were 
measured by a single question, similar to an item used by 
Gray et  al. [8], which asked clinicians how many GTTs 
they anticipated ordering in the next 12 months.
GTT‑related confidence
Two aspects of clinicians’ confidence in using GTT 
were assessed (Fig.  1). First, clinicians’ confidence 
or self-efficacy regarding their own ability to use 
GTT—which we designate “internal confidence”—
was assessed by three questions, adapted from Gray 
et  al. [8] The questions asked clinicians to rate their 
confidence in their ability to perform three tasks: (1) 
interpreting test results; (2) explaining test results to 
patients; and (3) using results to inform treatment deci-
sions (Cronbach’s α = 0.877). Second, clinicians’ con-
fidence in the ability of other stakeholders (including 
their practice and patients) to use GTT—which we 
designate “external confidence”—was assessed by three 
questions asking clinicians to rate their confidence in: 
(1) their practice’s ability to implement GTT; (2) their 
patients’ ability to understand GTT results; and (3) 
their patients’ ability to access targeted therapies and 
clinical trials (Cronbach’s α = 0.698). All answers uti-
lized a 5-point Likert scale; 0 = not at all confident to 
4 = extremely confident. For each construct, a summary 
score was calculated by averaging answers.
Attitudes towards GTT 
Clinicians’ attitudes regarding the value of GTT were 
assessed by 9 newly developed questions that our team 
adapted from attitudinal measures and findings of 
prior studies of physician and patient attitudes towards 
genomic testing [8, 18, 19]; the same questions were 
also asked of patient participants in this study. The 
questions asked clinicians to rate their agreement with 
4 positively and 5 negatively valenced attitudes (Fig. 2). 
The questions began with the statement, “Genomic 
tumor testing seems …” which was then paired with 
different adjectives (beneficial, harmful*, uncertain, 
accurate, trustworthy, unproven*, complicated*, ineffi-
cient*, and worthwhile). Ratings utilized a 5-point Lik-
ert response scale; 0 = strongly disagree to 4 = strongly 
agree. Negative items (identified above with an *) were 
reverse coded so that higher values corresponded to 
more positive attitudes. A summary score was calcu-
lated by averaging answers (Cronbach’s α = 0.698).
Fig. 1 GTT-related Confidence. Black dots represent means. Error bars represent standard error of the mean. Colored dots represent each 
participant’s response (position jittered to avoid overplotting). The x-axis labels reflect the response labels on surveys questions: 0 = not at all 
confident to 4 = extremely confident (intermediate options were not labelled)
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Perceived barriers to GTT implementation
Clinicians’ perceptions of barriers to implementing GTT 
in clinical practice were assessed by 17 questions that 
our team developed based on barriers identified in prior 
physician studies (Fig. 3) [9]. For each of these items, cli-
nicians were asked to rate their concerns about the use 
of GTT in their own practice using a scale of 0 = not at 
all concerned to 4 = extremely concerned. A summary 
score was calculated by averaging answers (Cronbach’s 
α = 0.832).
Data analysis
Descriptive statistics were generated to characterize 
the study population. Internal consistency reliability for 
the clinician perceptions and attitudes measures was 
assessed by calculating Cronbach’s α coefficient. Next, we 
fit linear regression models to identify factors associated 
with clinicians’ intentions to order GTT in the future. 
We first modeled clinician sociodemographic and prac-
tice characteristics (gender, years since medical school, 
practice size, rurality, and patient volume) alone, then 
added behavioral variables (summary scores for confi-
dence, attitudes, and perceived barriers) to the model. 
The distribution of the outcome variable (number of 
GTTs clinicians intend to order) was right-skewed; there-
fore, this variable was log-transformed for all models to 
meet normality assumptions. A value of 1 was added to 
all values to allow for zero values to be log-transformed. 
Coefficients reported here were transformed back (expo-
nentiated) to correct for the log-transformation, allowing 
the coefficients to be more easily interpreted. All analyses 
were conducted using R 3.5.3 [20].
Results
The study team identified 68 oncology physicians in 
Maine who were invited to join the Maine Cancer 
Genomics Initiative as of October, 2018. One physi-
cian was not currently engaged in clinical practice and 
was excluded from this analysis. Of the remaining phy-
sicians, 58 (87%) joined, consented to participate, and 
completed the survey (Table  1). The sample contained 
approximately equal number of women (48%) and men 
(52%), with an average of 19 years of practice since medi-
cal school (range = 4–45 years). The majority of partici-
pants were hematology/oncology specialists (84%), and a 
substantial proportion (62%) practiced in rural or small 
town settings. The average number of newly diagnosed 
patients seen for treatment evaluation each month was 
21 (range = 5–45).
Clinicians’ perceptions of GTT 
Clinicians had a generally high but variable confidence 
in their own ability to effectively utilize GTT (Fig.  1), 
Fig. 2 Attitudes about the value of GTT. Legend: * = items were reverse coded for aggregated measure and modeling. Black dots represent means. 
Error bars represent standard error of the mean. Colored dots represent each participant’s response (position jittered to avoid overplotting). The 
x-axis labels reflect the response labels on surveys questions: 0 = strongly disagree to 4 = strongly agree (intermediate options were not labelled)
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and relatively low confidence in their patients’ ability to 
understand GTT results and access targeted therapies 
(Fig. 1, Supplemental Table S1).
Despite their varying levels of internal and external 
confidence, clinicians generally had positive attitudes 
regarding the value of GTT. They showed high levels of 
agreement that GTT is beneficial, worthwhile, accurate, 
and trustworthy, and high levels of disagreement that 
GTT is harmful, causes issues with patient privacy, or is 
inefficient. There was variation in their level of agreement 
that GTT is uncertain, complicated, and can help most 
patients (Fig. 2, Supplemental Table S1).
Perceived barriers to GTT use also varied widely across 
clinicians. In general, clinicians were most concerned 
about the logistics of implementing GTT and the low 
likelihood of identifying clinically actionable results, and 
least concerned about the lack of patient interest, litiga-
tion, and patient privacy (Fig. 3, Supplemental Table S1).
Factors associated with intentions to use GTT 
Clinicians reported intentions to order an average of 26 
GTTs in the next 12 months (range 0–150). As noted 
above, the distribution was right-skewed with a few cli-
nicians ordering a large number of tests.
Multivariable regression analysis including only cli-
nician sociodemographic characteristics in the model 
showed no significant associations with GTT intentions 
(Supplemental Table S2). However, in the regression 
model including both clinician sociodemographic and 
psychological variables, future intentions to use GTT 
were significantly higher for clinicians with more prac-
tice experience (greater years since medical school): 
b = 1.04; 95% CI 1.01, 1.07; p = 0.020 (Table 2). Future 
intentions to use GTT were also significantly associated 
with greater internal confidence (i.e., their own ability 
to utilize GTT) (b = 2.07; 95% CI 1.24, 3.48; p = 0.007; 
Table 2), and with greater perceived barriers (b = 1.88; 
95% CI 1.07, 3.32; p  = 0.030). Future intentions were 
not significantly associated with attitudes regarding the 
value of GTT or external confidence (i.e., patients abil-
ity to understand results or access treatment and their 
practice’s ability to implement GTT) though there was 
a non-significant trend for both associations (Table 2).
Fig. 3 Perceived Barriers to GTT Implementation. Legend: Black dots represent means. Error bars represent standard error of the mean. Colored 
dots represent each participant’s response (position jittered to avoid overplotting). The x-axis labels reflect the response labels on surveys questions: 
0 = not at all concerned to 4 = extremely concerned (intermediate options were not labelled)
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Discussion
This study examined community-based oncology physi-
cians’ perceptions of GTT and how those perceptions 
relate to their intentions to use GTT in clinical prac-
tice. To our knowledge, this is the first study to include 
oncologists practicing in rural community settings, and 
to assess not only oncologists’ confidence in using GTT 
but also their attitudes towards GTT use, and their 
perceived barriers, and to examine how these factors 
relate to their future use of GTT. The study yielded sev-
eral findings that have important implications for the 
implementation of GTT in community oncology prac-
tice settings.
First, we found that more years since medical school 
was associated with greater intentions to order GTTs. 
This finding contrasts a nationally representative study 
which suggested that oncologists were more likely to 
order GTTs if they were younger than 50 years old [3]. 
This discrepancy may be due to differences in measures 
(e.g., dichotomized age vs years since medical school) 
and study populations. Interestingly, although a small 
study in Canada demonstrated rural-urban differences in 
genomic expertise and knowledge [14], our study showed 
no effect of rurality; however, our entire sample was 
arguably more rural than populations examined in other 
studies.
Consistent with previous research in academic phy-
sician populations [8, 12], we found wide variation in 
community-based oncologists’ confidence in using GTT. 
Clinicians in our study reported generally high levels of 
confidence in their own ability to use GTT, and lower 
confidence in patients’ ability to understand results and 
access targeted therapy. Although our goal was not to 
directly compare levels of confidence to those observed 
in other studies, when we rescaled rating of confidence 
to a shared 0–1 scale (0 = low confidence to 1 = high con-
fidence), clinicians in our study had very similar confi-
dence in their own abilities (Mean = .655) compared to 
clinicians in Gray et  al. (Mean = .667; see supplemental 
online materials for additional details) [8]. Also consist-
ent with findings from Gray et  al. [8] and as predicted 
by theories of health behavior [16, 17], we found that 
greater clinician confidence in their ability to use GTT 
(i.e., self-efficacy) was associated with greater future 
intentions to use GTT. Together, these findings suggest 
that the successful dissemination and implementation of 
GTT in community oncology settings might depend on 
increasing oncology clinicians’ confidence in using GTT, 
in addition to ensuring that patients are able to benefit 
from GTT. Clinicians’ internal confidence in GTT might 
be increased through various educational interventions, 
including genomic tumor boards, while their external 
confidence might be increased through the provision of 
patient-focused decision support or navigation services.
We also found that community-based oncologists had 
generally positive attitudes regarding the value of GTT. 
In health behavior theories, attitudes are important 
determinants of behavior [21–23]. Interestingly, how-
ever, in our study attitudes were not associated with 
clinicians’ intentions to order GTT. More research is 
needed to explain this lack of association, but one pos-
sibility is that other variables—such as local practice 
norms or the availability of GTT—may have greater 
influence on clinicians’ intentions and actual use of 
Table 1 Physician Demographic and Practice Variables
Number of responses: an = 52; bn = 52;cn = 47; dn = 47; en = 48; fn = 47
N (%)
Gender
 Female 26 (48%)
 Male 28 (52%)
 Missing 4
Rurality
 Rural 18 (34%)
 Small town 15 (28%)
 Suburban 12 (23%)
 Urban 8 (15%)
 Missing 5
Specialty
 Hematology/Oncology 48 (84%)
 Surgical Oncology 4 (7.0%)
 Gynecologic Oncology 2 (3.5%)
 No Specialty Identified 3 (5.3%)
 Missing 1
Practice Size (Number of oncology physicians)
 1–4 23 (45%)
 5–9 12 (24%)
 10+ 16 (31%)
 Missing 7
Years since medical school
 1–9 8 (15%)
 10–19 24 (44%)
 20–29 13 (24%)
 30+ 9 (17%)
 Missing 4
Mean (SD)
 Average number of newly diagnosed patients each 
montha
21 (10)
 Percentage of time spent on direct patient careb 88% (13)
 Patient Insurance Status (percent of caseload):
  Uninsuredc 12% (9)
  Medicaidd 22% (13)
 Commercially  Insurede 27% (10)
  Medicaref 44% (13)
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GTT. The relative lack of variation in clinician attitudes 
towards GTT in our sample may also have contributed 
to the observed lack of association between GTT atti-
tudes and intentions.
Our study also found wide variation in community-
based oncologists’ perceptions of barriers to utiliz-
ing GTT. Overall, the barriers of greatest concern were 
lack of insurance coverage and low probability of find-
ing actionable results. It is interesting that lack of insur-
ance coverage was considered a barrier of concern since 
the MCGI initiative offered free testing. Most likely, this 
concern existed before MCGI, and may return after the 
initiative ends. The barriers of least concern were lack 
of patient and colleague interest. Variants of unknown 
significance and managing patient expectations were 
barriers of moderate concern, mirroring findings using 
qualitative interviews [9]. Clinicians in our study also 
perceived incidental identification of germline muta-
tions as a barrier of moderate concern, similar to a study 
of patients [24]. Paradoxically, we found greater over-
all level of clinician concern about barriers to GTT was 
associated with greater intentions to use GTT. A possi-
ble explanation of this finding is that the level of concern 
about barriers to GTT may simply be a marker or result 
of greater use of GTT, rather than a cause. This finding 
raises the need for further research studies, using longi-
tudinal or experimental designs, that can establish the 
causal direction of these and other relationships. In any 
case, future efforts to disseminate and implement GTT 
in community oncology practice will need to address the 
perceived and real barriers to its use.
Limitations, strengths, and future directions
This study had several limitations that qualify the find-
ings and call for further research. First, the study was 
conducted as part of a broader implementation initiative 
that offered free GTT along with educational support 
(e.g. genomic tumor boards). Both of these factors may 
have influenced clinicians’ perceptions and use of GTTs, 
and may limit the generalizability of our findings to other 
practice settings. Furthermore, our study sample was 
relatively small and limited to a single state. For instance, 
we lacked power to explicitly test for differences between 
rural and urban practices, an important question that 
will need to be addressed by future studies. Addition-
ally, future work should test whether other variables, like 
the proportion of time clinicians spend on patient care, 
influence test ordering. Nevertheless, to our knowledge 
the current study is the first of its kind to enroll nearly all 
practicing community oncology physicians in a predomi-
nantly rural state, and was thus regionally representative. 
The current study was cross-sectional in nature; there-
fore, we cannot draw inferences about the causal direc-
tions of the observed associations. However, our study 
generates hypotheses that can be tested in more definitive 
future studies, which we will be conducting in the future 
using longitudinal data that is currently being collected. 
The current study also used intentions to order GTT as a 
proxy for actual GTT use; our future studies will address 
this limitation as well, by examining actual test-ordering 
behavior. Finally, because GTT is a relatively new inter-
vention in cancer care, many of our study measures were 
newly developed, and further research is needed to assess 
Table 2 Predictors of Intentions to use Genomic Tumor Tests in the Next 12 Months
1  Factor = exponetiated regression coefficient; every unit increase in the predictor variable is associated with a multiplicative effect of the coefficient on the number 
of GTT orders in the next 12 months
2  CI Confidence Interval
N = 48 due to some participants were missing data (see Table 1)
Factor1 95%  CI2 p‑value
Demographic Variables
 Gender
 Female – –
 Male 1.72 0.98, 3.03 0.061
Years since medical school 1.04 1.01, 1.07 0.020
Practice Size (Number of oncology physicians) 0.99 0.92, 1.07 0.8
Rural practice location 0.66 0.34, 1.26 0.2
Average number of newly diagnosed patients each month 1.01 0.98, 1.05 0.3
Psychological Variables
 Attitudes Summary Score 1.79 0.87, 3.68 0.11
 Confidence Summary Score - Internal 2.07 1.24, 3.48 0.007
 Confidence Summary Score - External 0.64 0.38, 1.08 0.094
 Barriers Summary Score 1.88 1.07, 3.32 0.030
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their reliability and validity. Despite these limitations, our 
study provides important new evidence on community-
based oncology physicians’ perceptions and practices 
regarding GTT, and the relationships between them.
Conclusions
Community oncologists’ perceptions of GTT vary widely, 
and their confidence in their ability to use GTT is asso-
ciated with their future intentions to order it. A bet-
ter understanding of these factors will enable clinicians, 
researchers, and health policy makers to address barriers 
to disseminating and implementing GTT in community 
oncology practice and to promote its appropriate use.
Abbreviations
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